Abstract: G protein-coupled receptors (GPCRs) represent a major class of drug targets. Recent investigation of GPCR signaling has revealed interesting novel features of their signal transduction pathways which may be of great relevance to drug application and the development of novel drugs. Firstly, a single class of GPCRs such as the bradykinin type 2 receptor (B2R) may couple to different classes of G proteins in a cell-specific and time-dependent manner, resulting in simultaneous or consecutive initiation of different signaling chains. Secondly, the different signaling pathways emanating from one or several GPCRs exhibit extensive cross-talk, resulting in positive or negative signal modulation. Thirdly, GPCRs including B2R have the capacity for generation of mitogenic signals. GPCR-induced mitogenic signaling involves activation of the p44/p42 "mitogen activated protein kinases" (MAPK) and frequently "transactivation" of receptor tyrosine kinases (RTKs), an unrelated class of receptors for mitogenic polypeptides, via currently only partly understood pathways. Cytoplasmic tyrosine kinases and protein-tyrosine phosphatases (PTPs) which regulate RTK signaling are likely mediators of RTK transactivation in response to GPCRs. Finally, GPCR signaling is the subject of regulation by RTKs and other tyrosine kinases, including tyrosine phosphorylation of GPCRs itself, of G proteins, and of downstream molecules such as members of the protein kinase C family. In conclusion, known agonists of GPCRs are likely to have unexpected effects on RTK pathways and activators of signal-mediating enzymes previously thought to be exclusively linked to RTK activity such as tyrosine kinases or PTPs may be of much interest for modulating GPCR-mediated biological responses.
Introduction
signaling routes [1] . In other cases, multiple receptors can converge on a single G protein which has the capability of integrating different signals [1] . Stimulation of a particular GPCR may result not only in activation of a single signaling pathway but also to subsequent interactions with those activated by the other GPCRs. These interactions between different receptor-coupled signal transduction pathways are termed cross-talk. In that way, synergistic interactions may be produced which result in an amplification of a coincident signal within the same cell playing a role in "fine-tuning" of multiple receptor-signaling pathways [2] . On the other hand, the signal transduction of one receptor may be also negatively regulated by that of another receptor, by feedback effects or by initiation of a parallel inhibitory pathway.
G Protein-coupled receptors (GPCRs) constitute a superfamily of transmembrane proteins that transduce extracellular signals to the intracellular level. More than 1000 of GPCRs are known up to now -tendency increasing. Their agonists differ in size and structure ranging from large glycoproteins to simple molecules such as amines or nucleosides. Agonist binding to a GPCR leads to activation of a heterotrimeric G protein, which in turn is linked to either activating or inhibiting second messenger pathways. The resulting change in second messenger concentration then leads to further downstream effector events, frequently activation of protein kinases.
In many cases a single receptor can activate different G proteins and thereby induce dual or multiple
Meanwhile it has become clear that GPCRs are not only involved in the regulation of metabolic or excitatory cellular responses but are also implicated in cell proliferation [3] (Fig. 1 ). Many ligands of GPCRs which are known as classical hormones or neurotransmitters, such as vasopressin, angiotensin II, endothelin, substance P, bradykinin, acetylcholin or serotonin, were found to elicit a mitogenic response in various cells [3, 4] . Thus, for example, the nonapeptide bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) which regulates blood pressure and smoooth muscle tone has been found to stimulate growth in small cell lung cancer (SCLC) cells [5] . There is increasing evidence indicating that GPCRs can function as agonist-dependent oncoproteins [6] . and subsequently activated [8] . GPCRs that mediate growth stimulatory effects activate key effector molecules of the MAPK pathway, including the RTK, Ras, Raf, or MAPK. Although MAPK activation may not be required for all GPCR-mediated growth responses, MAPK could be a convergence point of growthpromoting signals arriving from both RTKs and different GPCRs. Bradykinin, for example again, was also reported to stimulate MAPK activation, e.g. in fibroblasts [9] , SCLC cells [10] , or ventricular myocytes [11] . What are the mechanisms by which a GPCR can modulate cellular growth? One answer is cross-talk: Beside the interactions between different GPCR signaling pathways, stimulation of GPCRs may namely also result in activation of a pathway which receptor tyrosine kinases (RTK) employ for stimulation of cell growth, the so-called "MAP kinase (MAPK) pathway" [2, 4, 6, 7] . Growth factor RTKs frequently stimulate MAPK via recruitment of a complex of Shc, Grb2 and Sos proteins to the cell membrane, leading to subsequent activation of the small GTP-binding protein Ras, the two protein kinases Raf and MEK and finally of MAPK [8] . Once activated MAPK translocates to the nucleus where transcription factors are phosphorylated
In this review, we discuss principle signaling routes linking GPCRs to the MAPK pathway and, vice versa, leading to modulation of GPCR signalling pathways by RTK-induced tyrosine phosphorylation. As an example we will discuss the recent progress in the evaluation of cross-talk mechanisms between the bradykinin B2 receptor (B2R) and the EGF receptor (EGFR).
The majority of the modern pharmaca is targeted to GPCRs [12] . Uncovering of the complexity of GPCR signaling, of cross-talk mechanisms and of interaction with RTKs has interesting implications for drug development. Previously known GPCR effectors may have unexpected effects via affecting complex signaling networks. This may lead to unwanted side effects but also to novel applications of known drugs. Compounds affecting recently discovered GPCR signal transduction pathways as RTK transactivation may present paradigms for novel principles to modulate GPCR signaling.
6.
GPCRs with protease ligands that act through cleavage of the N-terminal segment which in turn activates the receptor (e.g. thrombin)
Within these subfamilies, the receptors for the various endogenous ligands may occur as receptor subtypes which are distiguished by their different pharmacological agonist and antagonist profiles, differences in their (cDNA-deduced) primary sequences, and in many cases in different signal transduction mechanisms [17] . For example, molecular exploration has revealed the existence of 9 subtypes of the adrenergic receptor (α 1A , α 1B , α 1D , α 2A , α 2B , α 2C , β 1 , β 2 , β 3 ), or 5 subtypes of the muscarinic receptor (M1-M5), or 7 subtypes of the opioid receptor (µ 1 , µ 2 , δ 1 , δ 2 , κ 1 , κ 2 , κ 3 ).
Basic Principles of GPCR Signal Transduction

GPCR Subfamilies and Receptor Subtypes
All GPCRs consist of an extracellular N-terminal segment, seven transmembrane helices (TM1-TM7), which form the TM core, three extracellular loops, and three loops and the C-terminal segment exposed to the cytoplasm. A fourth cytoplasmic loop may be formed when the C-terminal segment is palmitoylated at a Cys-residue. The seven TMs are arranged into a membrane-spanning boundle in the counterclockwise direction from TM1 to TM7 as viewed from the extracellular surface [13] . The N-terminal segment is the site of glycosylation and ligand binding, the Cterminal segment allows palmitoylation and phosphorylation as prerequisites for desensitization and internalization. The intracellular loops transmit the signal from the receptor to G protein. The TM core does not form a pocket or tunnel structure as conceivable but is tightly packed by hydrogen bonds and salt bridges [13] . There are several excellent reviews focussing on GPCR structure, conformation, and activation [13, [14] [15] [16] . On the basis of ligand binding and receptor activation several GPCR subfamilies have been classified [14, 16] :
For bradykinin, three receptor subtypes with distinct pharmacological profiles have been cloned [18] [19] [20] and characterized. The bradykinin B2 receptor (B2R) is constitutively expressed in various cells and mediates the physiological and pathophysiological effects of bradykinin such as vasodilation, bronchoconstriction, inflammatory reactions or pain sensations. Expression of the B1 receptor is only induced under pathophysiological conditions such as injury (for review see [21] ). In addition, there are presumably tissuespecific splice variants of the B2R [22] . Bradykinin Recently, a third type of kinin receptor was described in chicken and termed ornithokinin receptor [20] where bradykinin is inactive but the B2R antagonist Hoe 140 acts as full agonist.
The existence of receptor subtypes represent the first level of specificity in GPCR signal transduction: a single agonist may activate distinct signaling pathways via receptor subtypes which are encoded by different genes and display distinct coupling specificities.
1.
GPCRs with ligand binding to the core exclusively (photons, biogenic amines, nucleosides, lysophosphatidic acid, eicosanoids)
2.
GPCRs with ligand binding partially in both TM core and exoloops (short peptides) 2.2. Posttranslational Modifications of GPCRs:
Glycosylation, Palmitoylation and Phosphorylation
3.
GPCRs with ligand binding to the exoloops and the N-terminal segment (large polypeptides, e.g. glucagon)
The N-terminal segments of most GPCRs are glycosylated on asparagyl residues. Glycosylation may be important for the functional expression and cell surface localization of receptors [23] and may contribute to the ligand binding [24] , depending on the cell type.
4.
GPCRs whose ligands bind to the N-terminus exclusively (glycoproteins, e.g. LH, TSH)
5.
GPCRs whose ligands bind to a long N-terminal segment that subsequently interacts with the membrane-associated receptor domaine (small neurotransmitters) and Most GPCRs contain one or two conserved cysteine residues in their C-terminal cytoplasmic domain that appear to be generally palmitoylated. Palmitoylation is unique among lipid modification of proteins: it is reversible and adjustable [25] . There are several lines of evidence indicating that palmitoylation is important for intracellular trafficking of GPCRs and their cell surface expression but not for ligand binding or G protein activation [26, 27] . occupied receptor but also by other factors such as PKC or calmodulin [30] . Therefore, homologous or heterologous receptor phosphorylation on Ser-or Thrresidues might be an important mechanism in cross-talk regulation.
Tyrosine phosphorylation of GPCRs will be discussed in a later chapter of this article. Phosphorylation of GPCRs on seryl or threonyl residues represents a mechanism for the rapid control of receptor function and regulates the association of a GPCR with other proteins as well as their subcellular localization. This type of covalent modification terminates or attenuates receptor signaling via desensitization [28] . Receptor desensitization by phosphorylation is mediated either by G proteincoupled receptor kinases (GRKs) or by second messenger kinases [28, 29] . Heterologous desensitization of a particular GPCR is a feed back regulation by second messenger kinases such as protein kinase A (PKA) or protein kinase C (PKC) which may be activated via a signaling pathway of the target receptor or via a separate GPCR. Phosphorylation leads to changes in the receptor conformation and, subsequently, results in an impaired interaction with G proteins.
Heterotrimeric G Proteins as Signal Mediators
The heterotrimeric guanine-nucleotide-binding regulatory proteins (G proteins) are composed of a 36-52 kDa α-subunit, a 35-36 kDa β-subunit, and an 8-10 kDa γ -subunit. The β-and γ -subunits are assembled into βγ-complexes that act as functional units. G proteins are usually classified into four major subfamilies that share some common features: G s , G i , G q/11 and G 12 ( Table 1) . Multiple isoformes of each subunit have been identified up to date including 20 different α-, 6 β-and 12 γ -subunits. Interestingly, not all the possible combinations of β-and γ -subunits can be formed. G proteins underlie a cycle of activation and deactivation that transmits the signal from the receptor to the effectors (reviewed in [31, 34] ). Receptor activation triggers the exchange of GDP (bound in the inactive state) for GTP on the α-subunit of a G protein coupled to the receptor. This results in dissociation of the complex into receptor, GTP-liganded G α-and G βγ -units. The free receptor has a reduced affinity for its agonist which is released. G α -GTP and/or G βγ can interact with their target effectors. The slow intrinsic GTPase activity of G α terminates the α-induced effector association. G α-GDP re-associates the free βγ-complexes thereby also terminating βγ-mediated Ligand-induced or homologous desensitization requires GRKs and their functional cofactors, the arrestins. Both the GRK family and the arrestin family include at least six members [29] . In a first step the agonist-occupied receptors are phosphorylated by a GRK. Then, an arrestin binds to the phosphorylated GPCR and disrupt the interaction between receptors and G proteins. Desensitization represents the first step of internalization and down-regulation [28] . The cytosolically localized GRKs may be translocated to the membrane and thereby activated by the agonist- signaling. The reconstituted heterotrimeric G protein interacts again with the receptor and can begin the cycle anew.
The functional properties of G proteins are influenced by the covalent attachment of three types of lipids (for review see [35, 36] ). All α-subunits (with exception of transducin) are reversibly palmitoylated by labile thioester bonds to N-terminal cysteine residues. In addition, α-subunits of the G i/o family are myristoylated at conserved N-terminal glycine residues. This lipid modification is formed by a stable amide linkage and irreversible. The γ -subunits of all G proteins are prenylated by a stabile thioether bond between prenyl groups and cysteine residues. The precise function of these lipid modifications is not yet known but they appear to facilitate the targeting of G proteins to the membrane and the localization of G proteins to specific membrane subdomains, e.g. caveolae [36] .
Several of the α-subunits are substrates for covalent modifications by either cholera toxin (CTX) or pertussis toxin (PTX). CTX catalyzes the NAD + -dependent ADP-ribosylation of a conserved arginine residue of G αs and G αt proteins, resulting in an inhibition of GTPase activity and, therefore, constitutive activation of G α . PTX induces ADP-ribosylation of most G α -subunits of the G i/o -family (except of G αz ), which results in inhibition of receptor-G protein-coupling. These toxins are important tools for identifying and discriminating G protein-mediated responses. The α-subunits of G proteins have different contact regions to receptors, βγ-subunits, and effectors. There is accumulating evidence suggesting that a region of the C-terminal segment of G α is important for the coupling selectivity in receptor-G protein-interaction [37] . For example, in elegant molecular and biochemical studies has been shown that in α i/osubunits the C-terminal residues -4 (cysteine), -3 (glycine), and -1 (phenylalanine/tyrosine) and in α q/11 -subunits the C-terminal residues -3 (asparagine) and -5 (glutamate) play key roles in determining the receptor selectivity [38, 39] . The first 25 amino acids in the Nterminal part of α-subunits are essential for βγ-binding whereas the effector binding region partially overlaps the putative βγ-binding region. Therefore, the α-subunit cannot simultaneously bind effector and βγ [31] . In addition to the α-subunit, the C-terminal region of G β and the C-terminal part of G γ may be involved in receptor coupling and specificity [40] . two forms, R-I and R-II. The PKA-RI complex is cytosolically localized and its immobilization needs the interaction with additional regulatory proteins, the Akinase-anchoring proteins (AKAPs). The PKA-RII complex is particulate-associated. Thus, multiple isoforms of AC, PDE and PKA combined with spatial and temporal control provide an immense cross-talk potential of the cAMP system.
2.4.2.
Phospholipases, Lipidkinases, and Phospholipid-derived Second Messenger Systems Constitute Their own Signaling Network
The membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP 2 ) represents the substrate for phospholipase C (PLC). The hydrolysis of PIP 2 results in the simultaneous production of two second messengers, inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG), which mediate intracellular Ca 2+ -release and the activation of PKC, respectively [44] . To date 3 subfamilies of PLC are known including 4 PLCβ isozymes, 2 PLCγ isozymes, and 4 PLCδ isoforms (for review see [45] ). The PLCβ isozymes are activated by α-subunits of the G q/11 family but may be also stimulated by βγ-complexes of G q/11 , G i or G z proteins. The biological importance of PLCδ isozymes is not yet clear. It is assumed that activation of PLCδ might be an event secondary to receptor-mediated activation of other PLCs or Ca 2+ -channels [45] . The two PLCγ isozymes are structurally distinct from the other PLCs because they contain two SH2 domains and one SH3 domain (SH = Src homology; see next chapter). Thus, PLCγ is activated by RTKs of growth factors via binding to their autophosphorylated tyrosine residues and the subsequent phosphorylation of PLCγ at the tyrosines 771, 783, and 1254. The PLCγ isozymes may be also activated by nonreceptor phosphotyrosine kinases (PTKs) such as Src or Pyk2 (see also chapter 3). In various cells, these PTKs can be activated by GPCRs. In addition, PLCγ isozymes may be activated directly by several lipid-derived second messengers of GPCRs in the absence of tyrosine phosphorylation. Thus, GPCRs coupled to PLD or PI3-kinases may stimulate PLCγ through generation of their second messengers phosphatidic acid (PA) or PIP 3 , respectively [45] . Like AC-II, PLCγ represents a typical point of signal integration and may play a key role in cross-talk (Fig.  2B) . 
The Main Effector Systems of GPCR
Adenylate cyclase (AC)
Classically, adenylate cyclase responds to GPCRinduced stimulatory or inhibitory regulation, mediated either by G sα or G iα , respectively. Meanwhile at least 9 mammalian AC isoforms have been cloned and functionally characterized (for review see [41] [42] [43] ). All isozymes can be stimulated by G αs and, experimentally, with the plant diterpene forskolin (except AC-IX) but they differ in their response to other regulatory molecules. Based on their sequence homology, the ACs have been divided into several subfamilies with similar patterns of regulation. Adenylate cyclase type I (AC-I) can be stimulated by Ca 2+ /calmodulin and inhibited by G iα -and βγ-subunits. AC-II may be also activated by Ca 2+ /calmodulin but is not inhibited by βγ-complexes. AC-VIII defines ist own subfamily although its regulatory properties correspond to those of AC-III. Type V and VI AC constitute a subfamily that is only activated by G sα and may be inhibited by G iα as well as submicromolar concentrations of Ca 2+ but is insensitive to calmodulin and is not affected by βγ-complexes. The subfamily of AC-II, AC-IV, and AC-VII is insensitive towards Ca 2+ , can be stimulated by activated PKC and is sensitive to βγ-complexes which are capable of enhancing the stimulatory effect of G sα ( Fig. 2A) . The regulation of AC-IX is still unclear. In addition, cyclic nucleotide phosphodiesterases (PDEs) that play a crucial role in cAMP signal termination, are protein products of a multigene family displaying arround 30 isoforms [43] . The intracellular target of cAMP is protein kinase A (PKA) which consists of two cAMP-binding regulatory subunits (R) and two catalytic subunits (C). R exists in In addition to PLCs, PIP 2 serves also as a substrate for the receptor-regulated class I phosphoinositide 3-kinases (PI3Ks) which phosphorylate PIP 2 to PtdIns(3,4,5)P 3 (PIP 3 ) [46, 47] . One subtype of PI3K, the p110 PI3Kγ , has been shown to be directly activated by βγ-complexes from G i proteins [48] . In addition to PIP 3 production, this enzyme has the capacity to activate the MAPK pathway [49] . Two other isoforms, the PI3Ks α and β are dimeric molecules consisting of the p110 catalytic subunit and a p85 adaptor protein that contains two SH2 domains and links the p110 subunit to RTK signaling pathways. Recently it was reported that also the PI3Kβ can be alternatively activated by βγ-complexes from G proteins [50] . The PI3K-produced second messenger PIP 3 is rapidly degradated to PtdIns (3,4)P 2 , both molecules act as second messengers and can directly activate several PKC isoforms and/or the serine/threonine protein kinases PDK and PKB/Akt. Activated PKB/Akt provides a survival signal that protects cells from apoptosis [51] . PLA 2 to the membrane phospholipid substrate and requires also phosphorylation that is obviously catalyzed by activated MAPK (ERK2). PKC and PKA can phosphorylate PLA 2 in vitro but there is no evidence for a direct phosphorylation in vivo [60] . Nevertheless, PKC activation can lead indirectly to PLA 2 activation by triggering the MAPK pathway (see chapter 4). Activation of PLA 2 represents the direct pathway of AA release. Alternatively, AA may be released by a DAG-lipase from DAG which may be produced either via PLCβ, PLCγ , or the PLD pathway. AA from the various sources may be converted via the cyclooxygenase pathway , for example, to PGE 2 that can bind to and activate 4 different prostanoid receptor subtypes (EP [1] [2] [3] [4] [52] . PLD hydrolyzes phosphatidylcholine (PC) to phosphatidic acid (PA) and choline in a cell-specific response to various stimuli including thrombin, vasopressin, endothelin, angiotensin II or bradykinin. At least 3 mammalian PLD isoforms have been identified up to now (for review see [52] ). Downstream of GPCRs, PLD regulation occurs by activation via PKC or by activation via small G proteins such as ARF (ADPribosylation factor) or Rho (a monomeric G protein). PLD could contribute to the intracellular signaling by several mechanism. Firstly, PA has been implicated as a lipid second messenger in the regulation of protein kinases [54] activation of PLCγ [45] , and other signaling molecules, including the protein-tyrosine phosphatase SHP-1 [55] . Secondly, in most cells PA is rapidly converted to DAG through the action of phosphadidate phosphohydrolase. Thus, PLD-derived DAG is implicated in the late phase activation of PKC [56] . Thirdly, PA is converted to lysophosphatidic acid (LPA) by a specific PLA 2 . LPA is known as an intercellular signaling molecule that is rapidly released and affects cells by acting on ist own GPCR. LPA may be involved in the regulation of a variety of cellular responses, e.g. cell proliferation, smooth muscle contraction, platelet aggregation, or neurotransmitter release [57] . Interestingly, the LPA receptor is capable of coupling to both G i and G q/11 proteins thus activating dual pathways [57] . Therefore, LPA generated from PA is a typical example that a second messenger of a given GPCR signalling pathway may produce a mediator which acts through another GPCR in an autocrine or paracrine manner.
We have to go back once more to the G q/11 /PLC β -pathway which is chiefly producing the multiple second messengers IP 3 and DAG. IP 3 binds to a tetrameric IP 3 receptor in the endoplasmatic reticulum (ER) and triggers the release of Ca 2+ from the ER resulting in an intracellular increase in cytosolic Ca 2+ from approximately100 nM to approximately 1 µM. In terms of signalling, Ca 2+ has to bind to trigger proteins such as calmodulin that realize the messenger function of Ca 2+ (for review see [62, 63] ).
The intracellular target for DAG is protein kinase C (PKC) that belongs to the serine/threonine protein kinases. PKC is thought to be essentially involved in the regulation of cellular proliferation and differentiation. The PKC superfamily consists of several isoforms. Based on their domain structure and their regulation they have to be divided into at least 3 subfamilies: "convential" cPKCs (α, β I , β II , and γ ), which are sensitive to Ca 2+ , DAG, and phorbol esters; "novel" nPKCs (δ, ε, η, and θ), which are activated by DAG and phorbol esters but are independent of Ca 2+ ; and "atypical" aPKCs (ζ, λ, and µ), which are insensitive to Ca 2+ , DAG and phorbol esters and may be regulated by phospholipids, such as PA (for review see [56, [64] [65] [66] . Recently, the PKC superfamily was supplemented by the newly discovered PKC kinases (PRKs) consisting of at least 3 members (PRK 1-3 ) [66] . Like the aPKCs, they are insensitive to Ca 2+ , DAG and phorbol esters. Phorbol esters are potent tumor promoters and can substitute for DAG in activating cPKCs and nPKCs. They are not metabolized like DAG, evoke a prolonged activation of PKC and are useful tools in studying PKCregulated pathways in vivo.
Another phospholipase that is stimulated by numerous agonists of GPCRs but also by growth factors in a variety of cells is the cytosolic 85 kDa phospholipase A 2 (PLA 2 ) (for review see [58] [59] [60] ). Stimulation of PLA 2 leads to the release of arachidonic acid (AA) and, subsequently, to the production of eicosanoids [61] . Activation of PLA 2 by GPCRs requires increase in cytosolic Ca 2+ for the association of Thus, all signaling routes that generate DAG may result in the activation of distinct PKC isoforms. In addition, the PKC isoforms ζ, ε, and δ are known as targets for PIP 3 , the second messenger of PI3Ks [67, 68] . stimulation of AC whereas higher concentrations induce activation of PLC β [84] . The activation of multiple coupling GPCRs, consequently results in multifunctional signaling. Interactions between the particular pathways of a single GPCR with multiple signal transduction within the same cell could be classified as homologous cross-talk. Such interactions may occur at different levels of signal transduction. Recently, the group of Lefkowitz [85] has demonstrated that the β-AR can "switch" from G s to G i . The "switch on" of G i requires the proceeding activation of G s and the stimulation of the cAMP pathway. Activated PKA phosphorylates the β-AR leading to receptor coupling to G i . G βγ -complexes released from G i then activate MAPK in a Src-and Rasdependent manner [85] . Thus, this "switch on" mechanism induces cross-talk at the receptor level. Another example representing a "switch off" mechanism comes from our own work about BK signaling in A431 cells [76] . In this cell line, BK induces a rapid G q/11 -mediated activation of PLC β resulting in stimulation of PKC translocation. In a dual pathway BK slowly activates G s followed by an increase in cAMP production and PKA activation that leads to an inhibiton of PKC translocation (Fig. 3 ).
Finally, it should be noted that not only membrane enzymes but also K + and Ca 2+ channels may be effectors for GPCRs (for review see [69] ). Recently, also cross-talk at the level of Ca 2+ channels was reported resulting from PKC-mediated phosphorylation that antagonizes βγ-induced inhibition of Ca 2+ channels [70] . This cross-talk mechanism provides a first example that not only effector enzymes but also ion channels have the potential for the integration of multiple signaling inputs.
2.4.3.
Bradykinin B2
Receptor-mediated Signal Transduction
In dependency on the cell or tissue investigated the pleiotropic hormone bradykinin has been shown to be capable of activating different G proteins and multiple signaling pathways (Table 2 ). In the majority of cases, however, and in most cells bradykinin stimulates PLCβ via a G q/11 protein.
In addition, numerous interactions between signaling pathways of different GPCRs have been described (for review see [2] ). This type of interaction, therefore, could be classified as "heterologous crosstalk". Synergistic cross-talk between G i -and G qcoupled receptors, e.g. adenosine A 1 -or neuropeptide Y (NPY)-receptors and α 1 -adrenergic receptors often result in augmentation of physiological responses such as smooth muscle contractions [2] . Such synergistic interactions seem to play an important role in the "fine tuning" of multiple receptor signaling pathways [2] .
2.5.Complexity of GPCR Signaling: Multiple Coupling, Switching, and Cross-talk
It is well known that many individual receptors are capable of interacting with different G proteins [1, 83] . For example, the human thyrotropin (TSH) receptor or also the bradykinin B2 receptor (Table 1) can interact with members from each of the four major subfamilies of α-subunits. The specificity of interaction may be determined by the agonist concentration or by different kinetics. Thus, low concentrations of TSH lead to On the other hand, a single G protein can be activated by multiple receptors (Table 1) thus acting as convergence point [1, 83] . The specificity of receptor coupling to a mutual effector system may be determined by the composition of heterotrimeric G proteins. For example, using the antisense oligonucleotide technique Kleuss et al. [86, 87] showed in excellent studies that in GH 3 cells inhibition of Ca 2+ -channels by somatostain receptors is mediated by G o2β1γ 3 whereas inhibition by M4 muscarinic receptors is mediated by G o1β1γ 4 . Another mechanism for selective regulation of GPCR signaling pathways may be provided by the newly discovered RGS (regulators of G protein signaling) proteins [88, 89] . These RGS proteins function obviously as GAPS (GTPase-activating proteins) for heterotrimeric G proteins and and enhance the speed of GTP hydrolysis thereby controling the kinetics of G protein signaling. Members of the RGS family have been shown to display selectivity for different G α -subunits such as RGS2 for α q or RGS1/3 for α i [89] . Thus, the cellspecific expression of different GRS proteins may alow the independent control of multiple signaling pathways of GPCRs.
Receptor Tyrosine Kinase (RTK) Signaling and MAP Kinase Pathways
Ligand-dependent Activation of RTKs
Protein tyrosine kinases (PTKs) have central functions for the regulation of cell proliferation and other cell functions. Many polypeptidic mitogenic factors ("growth factors") elicit their cellular responses via receptors of the transmembrane receptor tyrosine kinase (RTK) family [90] [91] [92] . Well known examples are the receptors for epidermal growth factor [93, 94] , the platelet derived growth factors (PDGFs) [95, 96] or the fibroblast growth factors (FGFs) [97] [98] [99] . The biological effects of RTK stimulation include effects, largely positive, on cell proliferation ("growth"), cell differentiation, locomotion and cell survival (Fig. 4 ) . In contrast, receptors for cytokines, a class of growth-and differentiation-modulating polypeptides for hematopoietic and immune cells, are devoid of intrinsic enzymatic activity and need to recruit cytoplasmic PTKs for signaling [100] . While many aspects of signaling from RTKs and cytokine receptors have similarities, the latter class of receptors shall not be discussed further in this review. RTKs consist of an extracellular ligand binding domain, a single transmembrane domain and an intracellular domain which harbors the conserved tyrosine kinase subdomain and variable regulatory sequences [101] . The hitherto known molecules in this receptor family fall into 13 classes, assigned largely on the basis of homology within their intracellular tyrosine kinase domain [102] . More than 100 genes for RTKs may exist in the human genome [101] . The functional unit of an RTK consists of at least two receptor molecules or higher oligomers [103] [104] [105] . Receptor dimers or oligomers can be homomers or heteromers of related [106, 107] , possibly also of unrelated RTKs . In the absence of ligand, receptor dimer (oligomer) formation apparantly occurs spontaneously with low efficiency [108] . Solely overexpression of a given RTK may trigger sufficient dimer formation leading to signaling in the absence of a ligand [107] . This has frequently been observed in high level overexpression experiments [109, 110] and in cancer cells overexpressing an RTK. The receptors in the insulin receptor family [111, 112] present an exception since they consist of disulfid-bridged dimers in the absence of the ligand. Ligand bindig initiates signaling by triggering dimer/oligomer formation or, in case of the insulin receptor family, by triggering interaction of a preformed receptor dimer. Various molecular means are employed by RTK ligands to accomplish receptor dimer stabilization [105] . Monomeric ligands as EGF drive dimerization by interacting with receptor subunits in a 1:1 stoichiometry [113] . Dimerization may be consequence of conformational changes in the ligandoccupied receptors or may result from a bivalent interaction of both ligands with both receptor subunits in the dimer [114] . Other ligands are dimeric and interact with two receptor subunits at the time, as in case of PDGFs [104] .
As a consequence of receptor dimerization the two subunits trans-phosphorylate each other on tyrosine residues. Two types of phosphorylations can be distinguished: Phosphorylations in the "activation loop" in the kinase subdomain which lead to elevation of kinase activity and phosphorylations in other parts of the intracellular domain which create binding sites for signaling molecules. Crystal structures of the insulin receptor catalytic domain [115] and the FGF-receptor 1 catalytic domain [116] have revealed the mechanism of activation of these kinases [117] . The activation loop, a flexible structure identified in many protein kinases, in its unphosphorylated state can occupy partially (FGF receptor -1) or completely (insulin receptor) the active site of the kinase. Phosphorylation leads to displacement of the activation loop and in turn provides access for substrates to the kinase active site. A phosphorylation site corresponding to tyrosine 1162 in the insulin receptor kinase is conserved in RTKs suggesting that this mechanism of activation is a common principle. However, for example in case of the PDGFβ-receptor substantial residual kinase activity can be detected in a receptor variant with the 857 tyrosine (corresponds to 1162 in insulin receptor) mutated [118] or selectively blocked by a kinase inhibitor [119] . Thus, stringency of regulation by activation loop phosphorylation varies among the different RTKs. Multiple tyrosine residues can further be phosphorylated in the RTK cytoplasmic domains, both C-or N-terminally of the catalytic subdomain or, in RTKs with a split kinase domain as PDGF receptors, also in the "kinase insert" [95, 96] . These sites, in their phosphorylated form, present recognition and binding sites for signaling molecules posessing different types of phosphotyrosine binding domains as SH2-domains [120-122], or PTB domains [123, 124] . SH2 ("srchomology 2"-domains) are protein modules of about 100 amino acids which are found in numerous proteins and recognize phosphotyrosine in the context of up to 6 C-terminal amino acids. In contrast, PTB ("phosphotyrosine binding") domains recognize phosphotyrosine and 1-6 N-terminally situated amino acids. Another type of protein domains involved in signal transduction are SH3 ("src-homology 3") domains. They consist of about 60 amino acids and interact with other proteins in a phosphorylationindependent manner recognizing proline-rich sequences. These domains and a still increasing number of recently discovered protein-protein interaction domains are apparently required to achieve efficiency and specificity in highly ordered signal transduction complexes. Multiple interactions of the RTK cytoplasmic domains with signaling molecules form the basis for initiation of multiple intracellular signaling events (Fig. 4 ) . Several signaling chains may be necessary to elicit together a particular biological response. On the other hand, they form the basis for different types of biological responses which can be mediated via the same receptor as stimulation of cell growth, cell locomotion, cell differentiation and prevention of apoptosis.
Specificity and Redundancy in RTK Downstream Signaling
Downstream signaling molecules which bind to trans-phosphorylated RTKs fall in two classes: enzymes and adaptor molecules. An example for the former is the phospholipase Cγ [125] , which binds via tandem SH2-domains to different activated RTKs, is in turn phosphorylated and itself activated. An example for the latter is the p85 subunit of PI3kinase α, which docks to several growth factor receptors and permits in turn binding and thus membrane recruitment of the PI3 kinase catalytic subunit p110α [126, 127] . Adaptor molecules can also recruit further adaptors, which recruit other singaling molecules and so forth [122] . An example is the family of Shc adaptor molecules, which are phosphorylated subsequent to RTK binding and in their phosphorylated form are able to bind the adaptor molecule Grb2 [128] . Thus, RTKs present scaffolding molecules for the assembly of multiple signaling proteins which can interact in a chain of signal transduction events [129] .
Many RTKs have been shown to interact with the same set of signaling proteins. For example, Shc and Grb2 have been demonstrated to bind to multiple RTKs including the EGFR [130] , the EGFR-related receptor HER2/erbB2 [131] and the hepatocyte growth factor (HGF) receptor Met [132] . On the other hand, there are also pronounced specificities. Thus, PLCγ cannot bind to the insulin receptor [111] or Grb2 binds only with low affinity directly to the PDGFβ-receptor [133] . Certain RTKs have even quite specific interaction partners. The insulin receptor family RTKs accomplish most of their signaling activity via recruitment of relatively specific docking proteins, the insulin receptor substrates (IRS), which in their phosphorylated form then interact with further signaling molecules [111] . Other examples are the FGF receptor 1 which elicits much of its signaling via the FRS2 adaptor [134, 135] and the Met/HGF receptor RTK which exhibits a particularly strong interaction with the docking protein Gab1 [136] .
RTK Interaction with Further Protein Tyrosine Kinases
Another level of complexity of RTK signaling has emerged when it was found that RTKs utilize also cytoplasmic PTKs for signal transmission [137] . Cytoplasmic PTKs fall into 9 classes [102, 138] . Members of the Src-family of PTKs, comprising for example the intensely investigated PTK pp60 c-src (designated as "Src" throughout this review), its oncogenic counterpart v-Src and the PTKs Yes (pp62 cyes ), Fyn (p59 fyn ), Lyn (p56 lyn ) and Lck (p56 lck ) harbor one SH2-domain and one SH3 domain in addition to the catalytic domain. Negative regulation of these kinases occurs by phosphorylation on tyrosine residues in the C-terminus, leading to interaction with the intramolecular SH2-domain. Positive regulation is then possible by dephosphorylation of this phosphotyrosine by protein-tyrosine phosphatases (PTPs, see chapter 3.4). Src, Fyn and Yes may have apparently very similar functions. Several assays used for detecting involvement of Src in cellular functions cannot differentiate between these kinases. Another family of cytoplasmic PTKs is named after its prototype focal adhesion kinase (Fak), a 125kDa enzyme which cooperates with Src in integrin signaling and regulation of the assembly of cell-matrix adhesion complexes. A relative of Fak is Pyk2, a PTK which is activated by Ca2+ and likely to be involved in downstream signaling of some GPCRs. Finally, the family of JAK ("janus kinases") should be mentioned here, which includes also Tyk2 as a member. These PTKs function downstream of cytokine receptors but may also interact with some RTKs. A paradigm for interaction of an RTK with cytoplasmic PTKs present the PDGF-receptors which have the capacity to recruit Src family kinases, including p60 c-src and activate them in turn [139] [140] [141] . Src family kinase activation has been suggested to be essential for mitogenic signaling of the PDGFβ-receptor [142] . Similar observations have been made with the EGFR, although RTK-Src kinase complexes are less readily demonstrable in this case [142] [143] [144] [145] . Src-family kinases do appear, however, to not only simply mediate a signal but, to also phosphorylate the RTKs and thereby modulate signaling. Src phosphorylation sites have been mapped on the EGFR, the PDGFβ-receptor and the IGF-1 receptor [146] [147] [148] [149] [150] [151] . Mutation of a main Src-phosphorylation site on the PDGFβ-receptor leads to a reduced mitogenic signaling and a more pronounced stimulation of chemotaxis by PDGF via the mutant receptor [150] . For the EGFR and the IGF-1 receptor, increased RTK activity subsequent to phosphorylation by Src has been shown [146, 151] . Other cytoplasmic tyrosine kinases which have been shown to interact with RTKs are for example FER, a member of the fes/fps family of nontransmembrane receptor tyrosine kinases [152, 153] and possibly members of the JAK/Tyk family [154] .
exist which allow termination of signaling, and, evenly important, silencing of the RTK basal signaling activity in the absence of a ligand. Ligand-independent activation of RTKs [107] (discussed below) by various and quite diverse cell treatments including stimulation of GPCRs clearly shows that RTKs may have a signaling activity in the absence of ligand which is normally silenced. There are paradigms for negative regulation of RTKs at all levels of RTK activation, including interference with ligand binding [156] , with receptor dimerization [157] and with the tyrosine phosphorylations executed by the receptor kinase [158] . Also, receptor internalization [159] [160] [161] [162] [168] and may be an important general regulation principle.
Another means or negative RTK control are the actions of protein-tyrosine phosphatases (PTPs) (Fig.  4 ) . Since this type of interactions may provide an important link for cross-talk with the GPCR family of receptors (see chapter 4.4), we will describe it in some detail.
Ligand-activated RTKs are rapidly dephosphorylated by cellular PTPs, shown and investigated in some detail for example for the EGFR, PDGFβ-receptor or the insulin receptor [169] [170] [171] [172] [173] . Dephosphorylation parameters for not ligand-activated receptors are difficult to evaluate, however, treatment of cells with PTP inhibitors as vanadate [174] , phenylarsineoxide [175, 176] , hydrogen peroxide [177] or diamide [178, 179] leads to phosphorylation of many RTKs. Thus, "basal" activity of RTKs is probably quite significant and under negative control of PTPs. Over the last 10 years PTPs have emerged as a large family of quite diverse molecules [180] [181] [182] . More than 100 PTP species may exist [183] and hitherto almost 50 different individual PTPs have been shown to be expressed in a single cell type [184] . PTPs can broadly be classified in cytoplasmic and transmembrane, or "receptor-like" enzymes [185] . The former posess one PTP catalytic domain and various types of proteinprotein interaction or membrane targeting domains. The tramsmembrane PTPs have frequently two catalytic domains and variable extracellular domains. Depending on the PTP subclass, these may recognize cell surface proteins, matrix components or soluble ligands. For example, the PTPs RPTPµ and k have been shown to interact homophilically [186] [187] [188] . RPTPβ has a carboanhydrase-like motif in the extracellular domain which can interact with contactin, a
Inactivation Mechanisms for RTKs
Tyrosine phosphorylation needs to be tightly regulated. Loss of this tight regulation may lead to aberrant cell behaviour as uncontrolled proliferation. For many tyrosine kinases including RTKs oncogenic variants exist which have constitutive activity as a common property [155] . In case of RTKs, tight regulation is on the one hand provided by the necessity of ligand stimulation for activation. On the other hand, several negative regulation mechanisms neuronal cell surface protein [189] . Also, RPTPβ has been shown to interact with the matrix protein tenascin, cellular adhesion molecules (CAMs) and pleiotrophin, a heparin-binding neurite-promoting factor (reviewed in [190] ). Hitherto, it is unclear whether these interactions can affect intracellular PTP activity. From crystal structure data for RPTPα and from experiments with a chimeric molecule consisting of the EGFR extracellular domain and the RPTP CD45 intracellular domain it has been proposed that for certain RPTPs dimerization may lead to inactivation of the first (membrane-proximal) catalytic domain, which harbors most of PTP activity [191] [192] [193] . Among the cytoplasmic PTPs much attention has been devoted to SHP-1 (HCP, SH-PTP1, PTP1C) and SHP-2 (syp, SH-PTP2), the only known mammalian PTPs which posess SH2-domains [194, 195] . Their tandem SH2-domains target these PTPs to cellular phosphotyrosine-containing proteins including RTKs. Both PTPs exist in a relatively inactive "closed" conformation, with the N-terminal SH2-domain blocking the active site. Occupation of the SH2-domain leads to activation of PTP activity [196, 197] . SHP-2 is ubiquitously expressed and mediates positive signals for many RTKs and also cytokine receptors by a hitherto unknown mechanism involving the PTP catalytic activity. For some receptors, however, SHP-2 may also negatively control signaling steps (reviewed in [198] ). SHP-1 negatively regulates various types of receptors in hematopoietic cells, including immunoreceptors [199, 200] , cytokine receptors [201] , and the RTKs Kit/SCF-receptor [202] and CSF-1 receptor [203] . Apart from hematopoietic cells, SHP-1 is also expressed in epithelial cells [204] . It can associate with the EGFR and negatively regulate signaling of this receptor at least in cells with relatively high EGFR levels [55, 205, 206] . While SHP-1 has been assigned to various RTKs as a likely or possible negative regulator, in most cases the important PTPs for a given RTK signaling regulation are unknown. It is quite possible that several PTPs are involved in different aspects of signal regulation. The EGFR may serve as an example of this. In transient coexpression systems multiple PTPs have the capacity to dephosphorylate the receptor [109] . Interaction of the receptor has been described with the cytoplasmic PTPs SHP-1 and SHP-2 (via SH2-domains) [205] , PTP1B and T-cell PTP (with so-called "substrate trapping mutants" of the PTPs, forming stable enzymesubstrate complexes) [207, 208] and PTPs of the PTP-PEST-family [209] . Also, transmembrane PTPs are likely to modulate EGFR signaling. Inducible overexpression of the transmembrane PTP RPTPσ in A431 cells leads to reduced EGFR phosphorylation and a reduced capacity of the cells to form colonies in soft agar. Partial suppression of endogenous RPTPσ by inducible expression of an RPTPσ antisenseconstruct leads to elevated receptor phosphorylation and soft agar colony forming capacity [210] . Thus, RPTPσ appears to control aspects of EGFR signaling in A431 cells. Understanding regulation of PTP activity is only in its beginning. This concerns effects of known or putative ligands for RPTPs, mentioned above as well as possible effects of intracellular effectors. Activity of a number of PTPs has been shown to be modulated by Ser/Thr phosphorylation. For example, phosphorylation of SHP-1 by PKC leads to inhbition [211] , PKC-phosphorylation of the transmembrane PTP RPTPα to elevation [212] of PTP activity. Various PTPs are also phosphorylated on tyrosine residues, which has likewise been suggested do modulate activity [213] . Several cytosolic and transmembrane PTPs undergo partial proteolytic cleavages which modify cellular localization and may also affect activity towards cellular substrates [214] . Finally, lipid second messengers can modulate PTP activity as shown for phosphatidic acid and the PTP SHP-1 [55] . In conclusion, PTPs and regulation of their activity provide important but hitherto poorly understood pathways to modulate RTK signaling activity in a positive and negative manner.
RTK-mediated MAP-Kinase Activation
An important signaling pathway which links RTKs to cell proliferation and possibly other biological endpoints is the so-called "MAP-kinase cascade". This term refers to a signal transmission chain from the membrane to the nucleus, which is conserved from yeast to mammals and consists of a small G-protein followed by three consecutively activated protein kinases (for recent reviews see [215] [216] [217] ). In multicellular organisms RTKs have aquired the capacity to activate one variant of this chain, whose last enzymes in this case are the closely related Ser/Thrspecific; proline-directed "extracelluar signal regulated kinases" (ERKs) 1, and 2, also designated "mitogenactivated protein kinases" (MAPK) p44 and p42, respectively. In the literature frequently the term "MAP kinase" is used as a synonym for ERK1/2, as we do in the other chapters of this article. The main pathway for mitogenic signaling from RTKs like the EGFR or the PDGFβ−receptor involves the following steps: Subsequent to RTK activation and transphosphorylation occurs binding of a complex consisting of the adaptor molecule Grb2 and the guanine-nucleotide exchange factor (GEF) Sos for the small G-protein Ras. Ras, a 21kDa protein is the prototype for numerous small G-proteins in the cell (for review see [218] [219] [220] [221] [222] ). They all have in common that they are active, i.e. capable to interact with "effector proteins" in the GTP-loaded state. They have a small intrinsic GTPase activity, which is greatly enhanced by specific GTPase-activating proteins (GAPs). GTPloading of inactive, GDP-loaded small G-proteins is accomplished with the help of GEFs as the aforementioned Sos. Binding of the Grb2-Sos comples to the receptor is mediated by the Grb2 SH2-domain and can be either directly to the tyrosinephosphorylated RTK as in case of EGFR or indirectly via the phosphorylated adaptor Shc as in case of the PDGF receptor. Membrane-recruited Sos now enables a GDP-GTP-exchange on Ras. All this occurs at the inner surface of the plasma membrane, where Ras is bound via a farnesyl-anchor (Fig. 5 ) . GTP-loaded Ras has a high affinity for the first kinase in the MAPKcascade, the product of the cellular protooncogene craf, Raf-1 and recruits it to the membrane. Membrane recruitment of Raf-1 leads in an incompletely understood manner to activation of Raf-1. Probably additional proteins [223] and membrane lipids [224] as well as phosphorylation [225] contribute to activation of Ras-bound Raf-1. Activated Raf-1 phosphorylates its donwstream kinases MKK1or 2 (MAP-kinase kinase; also termed MEK for MAP/ERK-kinase) on two Ser residues, leading to activation of MKK. MKKs are kinases with "dual specificity", i.e. they can phosphorylate Ser/Thr and Tyr residues. Dual phosphorylation on Thr and Tyr in the activation loop of MAP kinases ERK2/1 confers ERK activation. Activated ERKs can phosphorylate multiple cellular target proteins, including transcription factors (subsequent to nuclear translocation of Erks), the p90 ribosomal S6 kinase (Rsk90), microtubule-associated proteins (MAPs) and phospholipase A2. These phosphorylations link activation of the MAP kinase pathway to cell growth and transformation. It should be noted that several members in the pathway upstream from Erks are transforming when overexpressed in a constitutively active form, including Ras, Raf and MEK, emphasizing that this is a main pathway for mitgogenic signaling.
Biological responses initiated via the MAPK pathway seem to critically depend on the duration of MAPK activation. For example in PC12 cells, sustained MAPK stimulation via the nerve growth factor (NGF) receptor TrkA leads to a differentiation response, while a short wave of MAPK activation via the EGFR mediates a mitogenic response. In other cells a sustained activation of MAPK may be necessary for eliciting a mitogenic response [226] . An intersting feature of the MAPK pathway is negative feedback regulation. Erks   Fig. (5) . MAP kinase pathways are routed by scaffold proteins and negatively controlled by multiple phosphatases.
can phosphorylate and thereby negatively regulate upstream molecules in the chain, notably Sos. Also, for example the EGFR can be phosphorylated on Thr 669 by Erk2. presents another level of regulation and possibilities for cross-talk with signaling pathways emanating from GPCR.
Ligand-independent Activation of RTKs
There are multiple variants of the MAPK signaling chain, starting with the existence of different isoforms of Ras, Raf, MKK, and ERK [217] . Parallel pathways on the basis of distinct members of the MAPK-family with corresponding upstream components and distinct downstream targets and biological effects exist. In yeast probably 6 members of the MAPK family exist [227] . They do not couple to RTKs (those do not exist in yeast) but to nutrient sensors or the pheromone receptor, a GPCR. In animal cells there are likewise multiple members of the MAPK-family. Other members, which are relatively well investigated apart from ERK1/2, are the NH2-terminal Jun-kinase/stress activated protein kinase (JNK/SAPK) and p38. Many RTKs can activate ERKs, some growth factor receptors have also been shown to activate JNK. JNK and p38 are both activated by various stress factors. In addition to ERK1/2 further MAPK-family members may be important for RTK signaling. For example the mitogenic signal of the EGFR has recently been shown to require activation of ERK5 (also known as "big molecular weight kinase" BMK) [228] .
Various quite diverse agents and cell treatments have been observed to induce activation of RTKs in the absence of ligand. These include cell treatments with "adverse agents", for example UV [235] or X-ray irradiation [236] . Also, activation of different GPCRs has been shown to lead to RTK activation. This pathway has been designated "transactivation" and is discussed in detail below (chapter 4.4). Finally, integrin and cellcell adhesion molecule activation have been shown to result in RTK activation [237] .
From the current knowledge of RTK activation and signaling control pathways different mechanisms could be envisaged for ligand-independent RTK activation: ligand-independent RTK dimer/oligomer formation, heterologous phosphorylations and inactivation of "silencing" mechanisms.
Some evidence has been obtained for the last possibility in case of UV-mediated RTK activation. PTPs which keep RTKs silent and inactivate them after ligand stimulation perform catalysis with particiation of a reactive cysteine in their active center and are therefore very susceptible to oxidation. UV treatment of cells could recently been shown to inactivate membrane bound PTPs for the EGFR and the PDGF receptor, most likely via an oxidative mechanism [110] . It seems quite likely that various adverse agents can lead to generation of reactive oxygen species and subsequently to PTP inactivation. These inactivation mechanisms may in fact be partially reversible and play even a role in ligand-activated signal transduction [238] . Hydrogen peroxide generation subsequent to RTK activation has been shown for the PDGF receptor to be essential for eliciting a mitogenic signal [239] . EGFR activation is accompanied by hydrogen peroxide generation [240] and a reversible inactivation of the PTP PTP1B [241] . PTP activity, however, is likely to be subject to regulation by further mechanisms, as phosphorylation or proteolysis, outlined above. This should in turn also modulate activity of PTP-regulated RTKs.
Specificity within a given MAP kinase cascade is on the one hand provided by specificities of the upstream and downstream elements for each other. On the other hand, scaffolding of different components of the chain by specific scaffold proteins seems to be an additional mean of providing specificity and efficient coupling of the signal transducing components [229, 230] . For example, MP1 and JIP1 are recently identified proteins which bind members of the ERK or JNK cascade, respectively, and may provide a scaffold for routing the signal within the cascade (Fig. 5 ) .
MAPK signaling is subject to negative regulation by phosphatases (reviewed in [231] ). One class of phosphatases responsible for inactivation of MAP kinases are the dual-specificity MAP kinase phosphatases (MKPs). Members of this family, for example CL100/MKP1 are products of "immeadiate early genes" which are rapidly activated upon growth factor stimulation. Multiple MKPs have pronounced selectivities for certain MAP kinase members and thus for feedback inhibition of the respective cascade [232, 233] . Also, PTPs can inactivate MAP kinases by dephosphorylating solely the phosphotyrosine in the MAPK activation loop [234] . Finally, the regulatory phosphothreonine on MAP kinase familiy members can be subject to dephosphorylation by Ser/Thr specific phosphatases [231] . In conclusion, inactivation of the MAP kinase cascades by phosphatases, either dualspecificity or tyrosine-specific or Ser/Thr-specific, An interesting question is to what extent heterologous tyrosine kinases may be capable of RTK activation. RTK phosphorylation by Src-family kinases is possible and may be sufficient to generate signal molecule docking sites and subsequent signal generation [137] . This would in principle be possible without participation of the RTK intrinsic tyrosine kinase activity. For the case of GPCR transactivation, however, participation of RTK intrinsic activity has been demonstrated (see chapter 4.4). It is an interesting possibility that Src-family kinases or other heterologous tyrosine kinases could also execute such RTK phosphorylations that would lead to RTK activation. Indeed, phosphorylation sites for Src on the EGFR are partially within the kinase domain and may regulate kinase activation [146, 148] . Also, PDGFβ-receptor was found to become phosphorylated on many sites including Tyr 857, the site presumably involved in kinase activation, by Src kinase in vitro [150] . Thus, Srcfamily kinases and possibly other tyrosine kinases may be capable of direct RTK activation although this possibility clearly requires further investigation. cell type to cell type. However, stimulation of various GPCRs was found to induce activation of key effector molecules of RTK signaling, including Ras, Raf, and MAPK. These observations led to the assumption that MAPK might be a point of convergence for proliferative signals emanating from both different G proteins and RTKs (Fig. 6 ).
It is thought that both the α-subunits and βγ-complexes of heterotrimeric G proteins are capable of mediating activation of MAPK. Obviously, in PTXsensitive pathways MAPK is activated through βγ-complexes from G i/o proteins whereas in PTXinsensitive pathways the activation of MAPK is mediated via α q/11 -subunits and PKC [4, 7, 8] . G smediated regulatory effects on MAPK activity may be either stimulatory or inhibitory. The role of G 12/13 proteins in MAPK activation is not yet clear. Very recently, the binding of G α12 to Bruton`s tyrosine kinase (Btk) and the stimulation of Btk and of Gap1 m which is a RasGTPase-activating protein (rasGAP) was reported [33] .
Signaling Pathways from GPCRs to MAP Kinase
Like RTKs, many GPCRs can induce mitogenic responses or contribute to neoplastic growth of human tumors (reviewed in [242] . Depending on the cell type, mitogenic responses can be mediated by G i/o , G q/11 , G s , or G 12 proteins. [4, 6, 79] . For example, constitutively active mutants of G protein α-subunits have been identified in various tumor cells, and GTPase deficient forms of G s , G i/o , and G 12 have been demonstrated to induce cellular growth after expression in several cell lines [243] .
These findings indicate, for the first time, the possibility of a direct link between heterotrimeric and monomeric G proteins.
Intensive research led to the identification of various protein kinases that could make the link between G proteins and the MAPK cascade. Recently, a novel principal pathway of MAPK activation has been discovered termed transactivation [243, 244] .
The pathways coupling GPCRs to nuclear responses are of high complexity and may differ from Transactivation stands for ligand-independent activation of RTKs triggered by GPCRs [107] . Despite the efforts made in the last years the early mechanisms of MAPK activation by agonists of GPCRs remain poorly understood. However, in the following we will attempt to describe the most likely biochemical routes connecting GPCRs to MAPK. addition, βγ-stimulated MAPK activation is inhibited by tyrosine kinase inhibitors such as genistein suggesting the involvement of a tyrosine kinase in this pathway [247] . Taken together, all experimental data led assume that Ras or an effector molecule upstream of Ras should be the target for the G iβγ -mediated mitogenic signaling. The question remained how the βγ-complexes might regulate Ras. First answer came from the laboratory of Lefkowitz. This group demonstrated that βγ-subunits stimulated tyrosine phosphorylation and thereby activation of the adaptor protein p52 Shc thus inducing the formation of ShcGrb2 complexes [249, 250] . Interstingly, G βγ -stimulated phosphorylation of Shc has been also found to be inhibited by Wortmannin, a specific inhibitor of PI3K suggesting an additional involvement of PI3K upstream of Shc [249] . Then Luttrell et al. [251] provided evidence that the non-receptor tyrosine kinase Src mediates the βγ-induced tyrosine phosphorylation of Shc. Later, several studies described the involvement of more Src-like kinases such as Fyn, Lyn, and Yes [252] or also, recently, of an unknown non-Src cytosolic tyrosine kinase that induces the interaction of a p100 kDa protein with Grb2 [253] .
Principle Mechanisms of MAPK Activation by G i/o -coupled Receptors
There are several lines of evidence suggesting that MAPK activation by G i -coupled receptors involves the βγ-complexes and is Ras-dependent. Thus, activation of MAPK via G i is attenuated by coexpression of the α-subunits of transducin which acts to sequester G βγ [245] . This was supported by similar results obtained in Rat-1 cells with βARKct, a carboxy-terminal fragment of the β-adrenergic receptor kinase that also acts as βγ-sequestrant and significantly inhibited activation of both Ras and MAPK via the G i -coupled LPA receptor [246] . Further, overexpression of G βγ subunits results in activation of MAPK [245, 247] whereas a constitutively active mutant of G iα did not increase MAPK activity in COS-7 cells [248] . It was demonstrated that MAPK activation by βγ-subunits required neither PLC β nor PKC (reviewed in [4] ) but was blocked by dominant negative Ras [245] . In Another candidate that has been implicated in ShcGrb2-Sos complex formation is the FAK-related non-receptor tyrosine kinase PYK2. This enzyme is predominantly expressed in neuronal cells and may link both G i and G q with Grb2-Sos in a Ca 2+ -and Srcdependent pathway as was shown for LPA-and BKreceptors in PC-12 cells [254] . independent or also Ras-dependent pathways [4, 7] . The Ras-independent pathway shows, e.g. in COS cells or CHO cells expressing G q -coupled receptors no sensitivity to a dominant negative mutant of Ras and may involve activation of PKC and Raf. G q -mediated signalling in CHO cells has been demonstrated to be inhibited by down-regulation of PKC by chronic exposure to phorbol esters and by dominant negative Raf [247] . Phorbol esters as direct activators of PKC have been reported to activate MAPK in various cells. In addition, expression of constitutively active mutants of PKC showed that at least in vitro the PKC isoforms α,β,δ, ε, and η have the potential to activate MAPK at the level of Raf-1. The aPKC ζ cannot increase Raf-1 activity and stimulates MEK by an independent mechanism [263] . Recently, much interest has been focussed at a possible role of the PKC isoforms α and especially ε as activators of Raf-1 in vivo. For example, a dominant negative mutant of PKC ε inhibited both proliferation of NIH 3T3 cells and Raf activation in COS cells whereas active PKC ε overcame the inhibitory effects of dominant negative Ras in NIH 3T3 cells [264] .
Furthermore, constitutively active mutants of PKCα as well as PKC ε overcame the inhibitory effects of dominant negative mutants of the other PKC isotype [264] . In addition, PKC ε can be co-precipitated with Raf-1 from Sf-9 insect cells and PKC ε transformed NIH 3T3 cells [265] . PKC ε was demonstrated to be activated by both phosphatidylinositol (PI)-and phosphatidylcholin (PC)-derived DAG [266] , and PChydrolysis was shown to induce Raf-1 activation [267] . Moreover, PKC ε may be also activated via the PI3K pathway thus representing a point of convergence for several lipid-derived second messengers. Taken together, there is increasing evidence that Raf-1 activation by PKC ε may play a critical role in mitogenic signalling of G q/11 -coupled receptors.
On the other hand, PI3Kγ has been shown to play a major role in G βγ -mediated activation of MAPK. Under endogenous conditions βγ-sensitive PI3K activity has been described in neutrophils and platelets [255, 256] , and PI3Kγ has been shown to activate MAPK when expressend in COS-7 cells in response to G i -derived βγ-complexes [49] . PI3Kγ can be activated due to direct interaction with βγ-complexes [48] or due to a constitutive association with the p101 βγ-sensitive protein [257] . PI3Kγ was found to act upstream of Srclike kinases suggesting another putative link to the Shc-Grb2-Sos complex [49] . Furthermore, we [258] and others [50, 259] have recently shown that the p85/p110 PI3Kβ may play a role downstream of G i -or G q -coupled receptor signalling, too. The putative signaling pathways connecting G i/o -coupled receptors to MAPK are summarized in Fig. (7 ) .
Very recently, once more the group of Lefkowitz provided evidence which probably opened a new dimension in our understanding of mitogenic signal transduction (reviewed in [260] ). Firstly, stimulation of β-adrenergic receptor expressed in HEK 293 cells resulted in a G i -coupled, βγ-mediated and Rasdependent activation of MAPK. However, the interaction of β-AR with G i required a prior receptor coupling to G s subsequently leading to cAMP production and activation of PKA. PKA-induced receptor phosphorylation was found to be a prerequisite for switching the receptor from G s to G i thereby activating another signaling pathway. [261] . Furthermore, in HEK 293 cells additionally expressing dominant negative mutants of β-arrestin or dynamin which are known to block receptor endocytosis the β-AR-mediated activation of MAPK was prevented [262] . The inhibitors of receptor internalization were found to specifically block the interaction between Ras-bound Raf and the cytosolic MEK. Thus, GRKs and arrestin mediating the uncoupling and internalization of GPCRs may play also an essential role in the GPCR-induced MAPK activation [260, 262] .
On the other hand, agonists of G q/11 -coupled receptors such as bombesin, bradykinin, or vasopressin as well as phorbol esters have been also described to stimulate Src family kinases transiently thereby activating MAPK in a Ras-dependent manner [268] . According to a hypothesis proposed by Della Rocca et al. [269] activation of Src kinases by G q/11 -coupled receptors might be the final event of a cascade including the increase in cytosolic Ca 2+ in response to IP 3 and the Ca 2+ -calmodulin mediated activation of Pyk2 or of a related tyrosine kinase which phosphorylates Src. Indeed, stimulation of G q -coupled BK receptors in PC-12 cells was demonstrated to activate PyK2 and subsequently Src and MAPK [254] . Src may phosphorylate either a RTK or Shc leading to the formation of a Shc-Grb2-Sos complex. The most likely biochemical routes connecting G q/11 -coupled receptors to The MAPK pathway are summarized in Fig.  (8 ) .
Principle Mechanisms by which G q/11 -coupled Receptors May Activate MAPK
Receptors coupled to PTX-insensitive G proteins of the G q/11 family are thougth to mediate MAPK activation via their α-subunits. Their signaling is mostly insensitive to βγ-sequestrants (reviewed in [4, 7] ). G q/11 -coupled receptors may activate MAPK by either Ras- 
4.3.
G s -coupled Receptors and MAPK: Differential and Controversial Effects of cAMP and βγ-Subunits released from G i after switching of β-AR from G s to G i [261] should mediate the activation of MAPK.
Very recently, a new family of cAMP-binding proteins was discovered that exhibit properties of a guanine necleotide exchange factor (GEF). These cAMP-GEFs are capable of activating monomeric G proteins in a cAMP-dependent and PKA-independent manner suggesting a direct coupling of cAMPmediated signaling to Ras superfamily signaling [276] .
The role of G s in the regulation of cell growth and MAPK activity appears to be extremely cell-type specific. In various cells such as smooth muscle cells [270] , adipocytes [271] , or fibroblasts [272] , cAMP has been shown to inhibit the MAPK cascade. In these cells, cAMP activates PKA which in turn phosphorylates Raf-1 thereby decreasing the affinity of Raf for Ras as well as Raf kinase catalytic activity [273] . In PC-12 cells, in contrast, cAMP stimulates the MAPK pathway and induces neuronal differentiation [274] . In COS-7 cells, Faure et al. [248] reported that the expression of a constitutively active mutant of G s , treatment with forskolin or dibutyryl cAMP, or stimulation of transiently expressed, G s -coupled LH receptor resulted in activation of MAPK. Contradictory results have been presented by Crespo et al. [275] suggesting dual effects of β-adrenergic receptors on MAPK activity in COS-7 cells. In this study, stimulation of β-AR simultaneously led to βγ-dependent activation and cAMP-mediated inhibition of MAPK. The balance between these two mechanisms was postulated do determine the outcome of the signal to MAPK [275] . However, in view of the present knowledge it may be assumed that not βγ-complexes from G s but those
A New Role for RTKs in GPCR Signaling: Different Pathways Lead to Transactivation
RTKs are not only receptors for specific peptidic growth factors but also essentially involved in the mitogenic signalling of GPCRs where they may act as scaffold proteins, signal mediaters, and signal integrators. First evidence for ligand-independent tyrosine phosphorylation of RTKs by a GPCR came in 1995 from reports demonstrating the tyrosine phosphorylation of PDGFR by angiotensin II [277] in rat smooth muscle cells or of EGFR by bradykinin in human keratinocytes [278] . Then, in two excellent papers, Daub et al. [243, 244] described the transactivation of EGFR in diverse cell types such as Rat-1 cells, HaCat keratinocytes, mouse astrocytes as well as in COS-7 cells (Fig. 9A ) . In Rat-1 cells it was shown that mitogens such as endothelin, LPA and thrombin mediate both MAPK activation and DNA synthesis via activation of EGFR [243] . In COS-7 cells transiently expressing G ior G q -coupled receptors was demonstrated that both types of GPCRs stimulated Shc phosphorylation as well as MAPK activity via EGFR transactivation [244] . Since inhibition of PI3K did not affect EGFR tyrosine phosphorylation but abolished MAPK activation PI3K was supposed to act downstream of EGFR. Similar results were obtained with the Src-inhibitor PP-1 leading to the assumption that also Src should be involved in the signaling pathway downstream of EGFR. Independently, Luttrell et al. from the Lefkowitz`group provided evidence that at least G icoupled receptors may induce EGFR tyrosine phosphorylation via Src-family tyrosine kinases [279] . They proposed, in contrast, that a PI3K-dependent step might lie upstream of Src kinase activation. Src kinase, indeed, possesses a domain with high affinity to PIP 3 the second messenger product of PI3K [280] . In contrast again, recently published data suggest that in HeLa cells the intrinsic EGFR tyrosine kinase contributes to the LPA-stimulated MAPK pathway and c-Src is probably not involved [281] . However, this finding in HeLa cells does not exclude that members of the Src family may be involved in other cell types. Furthermore, the same GPCR may induce transactivation of different RTKs depending on the cell type. This has been recently demonstrated for LPA which transactivates EGFR in COS-7 cells but is also capable of using the PDGFR in L cells that lack EGFR [282] .
was potently inhibited by a PKC inhibitor and the phorbol ester PMA could mimick the carbachol effect suggesting the PKC-dependency of EGFR tyrosine phoshorylation [284] (Fig. 9B) . A completely different mechanism of EGFR transactivation was found in GN4 rat liver epithelial cells where angiotensin II (A II) is capable of activating MAPK via two pathways. Under normal conditions, A II stimulates MAPK via a PKCdependent, Ras-independent pathway. In PKCdepleted cells, the A II receptor can switch and activates MAPK via an equipotent Ras-dependent pathway including EGFR tyrosine phosphorylation. Thus, the latent transactivation route represents an alternative pathway to MAPK that is masked by PKC and uncovered when the PKC pathway breaks down [285] (Fig. 9C) .
Moreover, in COS-7 cells transiently co-transfected with the human bradykinin B 2 receptor and MAPK we found a pathway of MAPK activation that includes the independent and equipotent stimulation of both PKC and EGFR [329] . Activation of MAPK in response to BK is prevented by inhibitors of PKC as well as EGFR. Inhibitors of PI3K or Src failed to affect MAPK activation by BK. PKC translocation studies and coexpression of inactive and constitutively active mutants of different PKC isoforms provided evidence for a critical role of the PKC isozymes α and ε in BK signalling towards MAPK. BK induced tyrosine phosphorylation of the EGFR that was independent of PKC. Since blockade of the EGFR did also not influence BK-stimulated increase in phosphatidylinositol phosphate formation, PKC should act neither upstream nor downstream of EGFR but in a permanent dual signalling pathway. MAPK activation by BK requires signals from both pathways which represent a two-key system for regulating an enzyme which is critically involved in the control of cell growth (Fig. 9D) .
In neuronal cells EGFR transactivation appears to be dependent on Ca 2+ . In PC-12 cells, for example, bradykinin-induced tyrosine phosphorylation of EGFR upstream of Shc and MAPK was reported [283] . This effect of BK was absent in PC-12 cells pretreated with EGTA. In other cells, however, EGFR transactivation was found to be independent of Ca 2+ [284] . In addition to the differences in Ca 2+ -sensitivity or the role of Src, the high degree of cell specificity within the mechanisms involved in EGFR transactivation by GPCRs is also reflected by different modes of action of PKC (Fig. 9 ) . Although activation of PKC has been widely shown to play a key role in MAPK activation by G q -coupled receptors, in COS-7 cells the G q -mediated transactivation of EGFR was postulated without any attempt to modify PKC activity in these cells [244] . This is surprising all the more because in 1995 Coutant et al. [278] already showed that in HaCaT human keratinocytes bradykinin induces tyrosine phosphorylation of EGFR via a PKC-dependent pathway. Similar results were reported for human 293 cells stably transfected with m1 muscarinic receptors. In these cells carbachol-induced EGFR transactivation As described above, a common theme in the literature on RTK transactivation by GPCR is the possible involvement of Src-family kinases. They may induce signal transduction by either phosphorylating RTKs on docking sites for signaling molecules or via direct activation of intrinsic RTK activity. As outlined in chapter 3, it is not entirely clear, how Src-family kinases can possibly accomplish RTK activation. One would have to assume that they execute phosphorylations of the RTK molecules which are functionally equivalent to trans-phosphorylations in RTK dimers. Such a model would be in agreement with some of the available data on Src-phosphorylation sites in different RTKs but this mechanism has not been fully established. Further, while tyrosine phosphorylation in the RTK "activation loop" has been established as activation mechanism for some RTKs as FGF receptor, insulin receptor or Met/HGF receptor, respective evidence is still missing for other RTKs. In fact, it is likely that for other RTKs, in particular EGFR regulation by activation loop phosphorylations is less important. Thus, the possible In contrast, it should be considered that a main pathway for RTK activation may be instead the interference with negative regulatory pathway mechanisms (see chapter 3.4) in particular with the activity of RTK-silencing PTPs. Their activity could well be affected by GPCR signaling events, as changed role of heterologous Src-kinase phosphorylations is even more questionable.
Ca2+-levels, lipid second messengers or various protein kinases including Src-family kinases. This kind of mechanism is not easy to demonstrate. EGF receptor dephosphorylation is a very rapid process [286] [287] [288] with t1/2 <<2min. It can be detected in intact cells as a decay of phosphotyrosine on the EGFR after quenching the kinase with specific cell-permeable blockers, subsequent to ligand stimulation [288] . A moderate attenuation of the dephoshporylation rate, in particular if it would affect only the not ligand-stimulated receptor, may be impossible to monitor with this technique. Use of general PTP inhibitors, on the other hand, will lead to rapid hyperphosphorylation of many cellular proteins which will likewise make conclusions as to the possible involvement of PTP in transactivation difficult. We believe, however, that the involvement of PTPs in GPCR-mediated RTK activation requires much attention and possibly the development of novel tools to monitor RTK-directed PTP activity.
additional proteins of interest in COS-7 cells or other transfectable cell lines. However, the procedure of transfection might and the overexpression of certain proteins will result in artificial and abnormal conditions within the cell compared with the native cell. Therefore, it should be considered that in general in overexpression models only signaling mechanisms can be detected which represent putative pathways which may not necessarily reflect the real situation under endogenous conditions. In natural cells or tumor cell lines expressing individual amounts of signal transducing molecules and different isoforms of effector molecules, for instance, completely different links between GPCRs and the MAPK cascade may be observed compared with the signalling pathways after stimulation of the same GPCR in an expression system. In order to demonstrate such conflicting findings in an expression model and in tumor cell lines two examples from our own work may be mentioned. Thus, in COS-7 cells transiently transfected with the human B2R bradykinin activated MAPK by a dual pathway and requires the independent signalling via both PKC and EGFR transactivation as described above. In contrast, when we studied MAPK activation in response to BK in the human colon carcinoma cell line SW-480 we detected a hitherto unknown biochemical route to MAPK [258] . Both BK-induced stimulation of DNA synthesis and activation of MAPK were abolished by two different inhibitors of PI3K, wortmannin and LY
Expression Models versus Endogenous Conditions: Varying Mechanisms of MAPK Activation by GPCRs in Tumor Cell Lines
The majority of models describing mitogenic pathways from a GPCR to MAPK are based upon experimental data obtained by coexpression of epitope-tagged MAPK together with GPCRs and often Fig. (10) . Bradykinin receptor signaling in the human colon carcinoma cell line SW-480. Here BK-induced activation of MAPK was found to be mediated via a pathway involving the consecutive stimulation of G q/11 protein, PI3Kβ, and PKC ε [258] .
294002, as well as by two different inhibitors of PKC, bisindolylmaleimide and Ro 31-8220. Furthermore, stimulation of SW-480 cells by BK led to both increased formation of PIP 3 and translocation of PKC ε that was inhibited by wortmannin, too. Using subtype-specific antibodies, only the p110 and p85 subunits of PI3Kβ but not p110 α or p110 γ were detectable in SW-480 cells. Finally, p110 β co-immunoprecipitated with PKC ε indicating a physical association between the two proteins. These results suggest a novel pathway involving the consecutive activation of G q/11 , PI3Kβ, PKCε, and MAPK (Fig. 1 0 ) . resulting in EGFR desensitization [289] . It may be concluded that BK affects the EGFR via both a decrease of tyrosine phosphorylation by enhanced PTPase activity and a decrease of EGFR sensitivity towards EGF by PKC. Although the EGFR is transinactivated by BK in A 431 cells, a BK-induced and PKC-mediated activation of MAPK was observed (Fig.  1 1 ) . These results provide evidence that not in all cases EGFR transactivation is necessary for GPCRinduced MAPK activation.
Additionally, a single agonist may also induce activation of MAPK by different signalling pathways which can vary between different cell types stimulated. For example, in GN4 cells the angiotensin II (AII) receptor was reported to stimulate MAPK via a dominant PKC pathway and a latent EGFR transactivation pathway as already discussed [285] . In rat cardiac myocytes, AII was found to activate MAPK via PLC β , PKC, and Raf-1 independently of EGFR [290] . In contrast, in rat vascular smooth muscle cells a pathway from AII receptor to MAPK was detected involving the sequential activation of G q/11 , PI3K, PKC ζ, and an association of PKCζ with Ras suggesting a PKC/Ras dependent pathway that can by-pass the EGFR [291] . Further, in rabbit renal proximal tubular Another cross-talk mechanism between B2R and the MAPK pathway we observed in A 431 cells [Graneß A.; Hanke S.; Boehmer F.-D.; Liebmann C.; in press]. In this cell line BK induced a decrease in both basal and EGF-stimulated tyrosine phosphorylation of EGFR by stimulating the activity of a phosphotyrosine phosphatase. This effect can be demonstrated by several experimental approaches including the respective Western blots of EGFR as well as direct measurement of PTPase activity using the [ 32 P] tyrosine-phosphorylated PTPase substrate raytide. Moreover, BK was previously shown to also induce a PKC-mediated phosphorylation of EGFR at Thr-654 Fig. (11) . Bradykinin B2 receptor signaling in the human epidermoid carcinoma cell line A431. BK attenuates EGFR by both stimulation of PTP and of PKC. Activation of PTP results in a decreased tyrosine phosphorylation of EGFR and activated PKC induces threonine phosphorylation of EGFR that leads to its desensitization towards EGF. Nevertheless, BK is capable of stimulating MAPK activity via another PKC-dependent pathway. This is an example for a simultaneously occuring negative modulation of EGFR (transinactivation) and positive regulation of MAPK activity by a GPCR in a cell-specific manner.
epithelial cells, AII activates MAPK via the AT 2 receptor subtype and a signaling route involving stimulation of G i and, subsequently, PLA 2 , the release of arachidonic acid which in turn activates Shc and Ras [292] . In N1E-115 neuroblastoma cells AT2 receptors mediate inhibition of serum-or EGF-induced MAPK activation, possibly via activation of a PTP (293) .
Whereas the AT 1 receptor preferentially couples to G q/11 proteins, in colonic epithelial cells also the G i protein-coupled gastrin receptor was found to stimulate PLC γ 1 via Src [295] . It may be assumed, therefore, that both G q/11 -and G i -coupled receptors have the ability to act without G proteins by forming signal transduction complexes which are thought to be typical for RTKs. On the other hand, with respect to ligand-induced tyrosine phosphorylation of the B 2 bradykinin receptor contradictory results have been reported. In human fibroblasts the B2R was shown to be phosphorylated at serine and threonine residues in response to BK and neither phosphoamino acid analysis nor Western blotting with anti-phosphotyrosine antibodies revealed tyrosine phoyphorylation of the B2R [298] . In contrast, in endothelial cells the BK-induced IP 3 formation was reported to be dependent on a transient tyrosine phosphorylation of PLC γ 1 [299, 300] . In vascular endothelial cells, tyrosine phoyphorylation of PLC γ 1 could be correlated with its binding to the C-terminal intracellular domain of the B2R similar to the findings at the AT 1 receptor [300] . Unfortunately, there is no clear evidence for a ligand-induced tyrosine phosphorylation of the B2R in this work.
These few examples may illustrate by which immense complexity and cell specificity the cross talk between GPCRs ant RTKs can occur.
RTK-induced Tyrosine Phosphorylation of GPCR Signaling Elements
Although relatively much is known about the interaction of GPCRs with RTKs and the MAPK cascade, the modulation of GPCR-coupled signal transduction by RTK-induced tyrosine phosphorylation is considerably less investigated. Meanwhile, however, there is mounting evidence that cross-talk includes not only the foreward regulation of the MAPK pathway by GPCRs but also the regulation of GPCR signaling by RTKs. Recently, at least three levels of GPCR signal transduction were implicated to be favoured targets of tyrosine phosphorylation by RTKs.
It is worth to speculate, however, that tyrosine phosphorylation of GPCRs might occur not only ligandinduced (homologous) but also as a cross-talk event induced by activated RTKs (heterologous). In that way, a RTK could use tyrosine-phosphorylated GPCRs as scaffold proteins for ist own signal transduction machinery.
Tyrosine Phosphorylation of GPCRs
G protein-coupled receptors lack intrinsic tyrosine kinase activity. Nevertheless, several agonists of GPCR such as angiotensin II [294] or gastrin [295] have been demonstrated to stimulate phosphatidylinositol metabolism by a signalling mechanism that involves PLC γ and Src instead of PLC β . In vascular smooth muscle cells, for example, the AT 1 receptor was demonstrated to induce a transient tyrosine phosphorylation of PLC γ 1 and a parallel IP 3 formation in a manner similar to that observed in response to growth factors [294] . In addition, electroporation of antiSrc antibodies into these cells eliminated both tyrosine phosphorylation of PLC γ and AII-induced stimulation of IP 3 production suggesting that activation of PLC γ occurs downstream from activation of c-Src tyrosine kinase [296] . Very recently, the activation of PLC γ by AII was found to be accompanied by binding of PLC γ to the AT 1 receptor in dependency on AII stimulation as well as tyrosine phosphorylation. A prerequisite of PLC γ 1 binding appears to be phosphorylation of tyrosine 319 in a YIPP motif in the C-terminal intracellular domain of the AT 1 receptor. This phosphorylated tyrosine residue can be recognized by a SH2-domain of PLC γ 1 [297] . It might be speculated that the receptor serves as a scaffold for PLC γ 1 allowing its phosphorylation by Scr tyrosine kinase.
Tyrosine phosphorylation of G proteins
Like other signalling proteins, also G proteins may be phosphorylated and thereby modulated by different protein kinases. Thus, phosphorylation of G iα by PKA appears to impair the dissociation of G i into α-and βγ-subunits [301] . In contrast, the α-subunits of G z as well as G 12/13 are phosphorylated by various isoforms of PKC resulting in a prevention of their association with βγ-subunits [302] [303] [304] . In addition, recombinant forms of G sα were shown to be targets for PKC in vitro suggesting a putative role of G sα within the cross-talk between receptors which activate PKCs and those which stimulate adenylate cyclase via G s [305] .
First evidence concerning tyrosine phosphorylation of G proteins was provided in 1992 by Hausdorff et al. [306] . They demonstrated in vitro the tyrosine phosphorylation of G sα as well as other G α subtypes (G iα , G oα ) by activated Src. As a functional consequence, phosphorylation of G sα was found to increase receptor-induced GDP/GTP exchange and GTPase activity. Three years later, Moyers et al. [307] identified the in vitro phosphorylation sites of G sα mediated by Src. In an excellent work two sites of phosphorylation were mapped, Tyr-37 located near the N-terminus and Tyr-377 located at the site of receptor binding in the C-terminus. Tyrosine phosphorylation of G sα , at these sites, therefore, could change its ability to interact with both βγ-subunits and the receptor [307] . Almost at the same time the tyrosine phosphorylation of recombinant G sα by isolated EGF receptor tyrosine kinase was reported [308] . Tyrosine-phosphorylated G sα showed enhanced GTP binding and GTPase activity and an increased degree of adenylate cyclase stimulation after reconstitution with S49 cycmembranes [308] . These findings suggested that also a RTK has the ability to phosphorylate and thereby to activate G sα . In 1996, too, using several experimental approaches we provided the first evidence for tyrosine phosphorylation of G sα in A431 cells in vivo [309] . Treatment of A431 cells with EGF abolished both bradykinin-and isoprenaline-induced binding of the stabile GTP analogon [ 35 S]GTPγ S to G sα and decreased the BK-and guanyl nucleotide-induced cAMP accumulation and adenylate cyclase stimulation. In contrast, the BK-induced and G q/11 -mediated formation of inositol phosphates was not affected by EGF. Thus, tyrosine phosphorylation of G sα by EGF results in an activation of adenylate cyclase by EGF, on the one hand, and a simultaneously occuring loss of the susceptibility of G sα to GPCRs (Fig. 1 2 ) . These findings emphasized a differential recruitment of G sα by GPCRs and EGFR as a novel cross-talk mechanism.
Moreover, also G q/11 appears to be tyrosine phosphorylated. Recently, stimulation of GPCRs coupled to G q/11 was shown to induce phosphorylation on Tyr 356 and a PTK is required before G protein activation. It was further demonstrated that this tyrosine phosphorylation is apparently essential for the activation of G q/11 by agonist stimulation [310] . These results demonstrate that tyrosine phosphorylation of The G αq/11 subunit by PTKs contributes to GPCRmediated activation of G q/11 .
Taken together, it may be assumed that depending on the type of G protein and the type of cell both GPCR-induced ( probably mediated by Src, Pyk2 or others) and/or RTK-induced tyrosine phosphorylation of G α -subunits might represent a mechanism to regulate the activation of G proteins.
Tyrosine phosphorylation of PKCs
Tyrosine phosphorylation of PKC isoforms such as δ, ε, η, and ζ in response to Src family tyrosine kinases in vitro has been reported [311] but the biological Fig. (12) . EGFR-induced tyrosine phosphorylation of G sα in A431 cells is accompanied by a loss of the susceptibility of α s to activation via GPCRs and its ability to stimulate adenylate cyclase in response to activated GPCRs [309] . significance remains unclear. In transiently transfected COS-7 cells overexpressing various PKC isoforms the PKCs α, β 1 ,γ , δ, ε, and ζ were found to be tyrosine phosphorylated and catalytically activated in response to H 2 O 2 that is known to induce oxidative stress [312] . However, the tyrosine kinases that phosphorylate PKC isoforms under these conditions are not yet known. Among the PKC isoforms which are tyrosine phosphorylated in vitro some interest has been focussed to PKCδ. This isoform has been shown to be phosphorylated on tyrosine in Ras-transformed cells [313] and in response to various stimuli such as phorbol esters, carbachol, or substance P [314] . In addition, PKCδ is tyrosine phosphorylated after stimulation of the EGFR signalling pathway involving the activation of a member of Src kinase family and leading to inhibition of PKCδ activity [311] . In v-Srctransformed fibroblasts the formation of a Src-PKCδ complex in which PKCδ becomes tyrosine phosphorylated and down-regulated was proposed as a possible molecular mechanism [315] . As PKCδ phosphorylation sites Tyr 52 and Tyr 187 in the N-terminal part have been identified [316, 317] . However, the functional consequences of PKCδ tyrosine phosphorylation remain controversial and involve both activation and inhibition of catalytic activity.
on GPCR directed drug development. Cross-talk beween different GPCRs and the discovery of multiple pathways initiated by a single class of GPCR predict that GPCR agonists/antagonists will have side effects depending on the given coupling of the GPCR to signaling pathways, even if they target a given receptor subtype with absolute specificity. An example comes from the bradykinin story. B2R antagonists have a therapeutic potential as novel analgetic and antiinflammatory agents. Structural modifications of BK led to the discovery of the peptidic B2R antagonist Hoe 140 which is highly potent and specific in all cells and tissues tested so far. When we screened various tumor cell lines for mitogenic effects of BK we used Hoe 140 as control. Very surprisingly, we found that in certain tumor cells the antagonist Hoe 140 induced stronger mitogenic effects than BK (C. Liebmann, unpublished results). On the other hand, understanding of GPCR post-receptor signaling mechanisms opens up the possibility to interfere with downstream signaling steps. This concept has been put forward as "signal transduction therapy" initially mainly focussed on RTK signaling [318] , where development of efficient ligand antagonists hitherto failed. Inhibitors of enzymes mediating important steps of GPCR signaling would block receptor effects. Alternatively, inhibition of negatively regulating steps could be used to augment signaling of a given GPCR. Interstingly, the recent findings on GPCR cross-talk with RTKs has brought into play specific tyrosine kinase inhibitors as a novel class of effectors for GPCR signaling [319] [320] [321] . These drugs have actually been instrumental for clarifying the involvement of RTKs in aspects of GPCR signaling, notably mitogenic signaling of GPCR. Such compounds are for example specific inhibitors for the EGFR of the anilino quinazoline family as AG1478 or PD153035 (Table 3) , specific inhibitors of the PDGF receptors as the quinoxaline AG1296 and the phenylaminopyrimidine CGP53716 [322] or the Srcfamily inhibitor PP1 [323] . The latter has, however, recently been found to block the PDGFβ-receptor as well [287] . Another class of kinase inhibitors with increasing relevance for GPCR signaling are blockers of enzymes in the MAPK signaling cascades, including the inhibitor of MEK1/2 PD98059 [288] or the specific p38-blocker SB203580 [324, 325] . One can anticipate that the current rapid development in the field of kinase inhibitors will certainly be of great value for the pharmacological modulation of GPCR signaling.
Nevertheless, these findings implicate the possibility that PKC may be regulated by different signalling pathway in response to stimulation of GPCRs as well as RTKs. One is the classical DAG-dependent pathway through activation of PLC β/γ or PLD. Another signalling route may occur DAG-independent but involving activation of PI3K. A third pathway might be the tyrosine phosphorylation of PKCs in response to RTKs stimulated directly by growth factors or transactivated via GPCRs.
Nevertheless, these findings implicate the possibility that PKC may be regulated by different signaling pathways in response to stimulation of GPCRs as well as RTKs. One is the classical DAGdependent pathway through activation of PLC β/γ or PLD. Another signaling route may occur DAGindependent but involving activation of PI3K. A thrid pathway might be the tyrosine phosphorylation of PKCs in response to RTKs either stimulated directly by growth factors or transactivated via GPCRs.
Implications for Drug Development
Several kinase blockers have recently been put forward to clinical trials, maily aiming at tumor therapy by targeting RTK pathways [326] . Since, however, as outlined above, pathways from GPCRs and tumorrelevant RTKs converge, overlap and cross-talk, one could anticipate that GPCR-related side effects may become observed.
Activity of GPCRs can be selectively modulated by receptor-subtype specific agonists or antagonists. Numerous drugs have been developed on the basis of this principle. Progress in understanding of GPCR signal transduction pathways creates new perspectives As we have tried to illustrate, GPCR signaling is a pleiotropic response which, as a rule, involves multiple signaling chains. To what extent these pathways are activated strongly depends on the cell type concerned. Thus, interference with GPCR signaling is likely to require a "cocktail" of signaling effectors which is tailored for a given target tissue.
signaling mechanisms have been performed in permanent cell lines or overexpression systems and some if not many proposed mechanisms may reveal to be not physiologically relevant. In conclusion, predictions on selective in vivo effects of certain effectors are currently hardly possible. Generation of transgenic mice with inactivated genes for certain signal-mediating molecules has revealed, however, that the effects of even complete abolishment of certain signaling steps in all tissues may be much more selective than previously anticipated. An example is the recent inactivation of the gene for p85α, an adaptor molecule required for activation of the α and β-isoforms of PI3 kinase [328] . This knockout led not to lethality, as might have been anticipated but to a specific impairment of B-cell immunity. One has further to consider, that application of a signal transduction enzyme inhibitor in vivo is unlikely to lead to complete ablation of enzyme activity, rather more attenuation in some tissues and less attenuation in others, depending on pharmacokinetic parameters and expression levels. This leaves further possibilities for specific effects.
Frequently, pharmacological modulation of GPCR signaling aims at stimulation or augmentation of receptor function. Compounds affecting enzymes which regulate signal transduction negatively would be excellent tools in this respects. However, effector discovery for such enzymes is only in its beginnings. This concerns inhibitors of PTPs, of MAPK inactivating dual-specificity phosphatases, of inositolpolyphosphate phosphatases, of phosphatidylinositolphosphate phosphatases and others. An exception present inhibitors of phosphodiesterases, where a number of compounds are in clinical trials and one drug has recently been introduced to the market [327] . This example illustrates the immense possibilities for drug development aiming at interference with negatively regulating signaling events.
In conclusion, development of further signal transduction effectors for GPCRs seems highly warranted although the only partially understood complexity of signaling makes predictions of in vivo effects and disease indications difficult. It can, however, be anticipated that many reasonably target selective compounds will eventually find applications.
One could assume that specificity for signal transduction therapy will be the more difficult to attain the further distal to the GPCR the targeted signaling step is positioned. As outlined above, it becomes, however, increasingly clear that the pathways used by a given GPCR, the extent of cross-talk and feedback reactions, are to a very high degree cell-specific. Thus, interference with a given enzyme is likely to have very different effects in different cell types and beneficial effects may be obtained in a particular tissue whithout negatively affecting others. It is difficult to predict to what extent inhibition of a certain signaling step will abolish signaling or rather shift signaling to another pathway. Also, partial inhibition of a pathway which contains negative feeback elements may affect feeback inhibition to a greater extent than positive signal generation and thus, lead to even augmented signaling as net result. Further, most studies on
Note Added in Proof
A novel mechanism for EGFR transactivation by GPCRs has been shown recently: GPCR-dependent activation of a metalloproteinase leads to processing of pro-heparin-binding (HB)-EGF and EGFR activation by released HB-EGF. This process is suppressed by the metalloproteinase inhibitor batimastat. 
